Biochanin A (Isoflavone · Phytoestrogenic · Aromatase Inhibitor)

Compound	Biochanin A (5,7-Dihydroxy-4′-methoxyisoflavone; Genistein 4′-methyl ether)
Chemical class	Polyphenol — Isoflavone (O-methylated genistein; red clover characteristic isoflavone)
CAS	491-80-5
Primary source	Trifolium pratense (red clover), Cicer arietinum (chickpea), Cajanus cajan (pigeon pea)
Key applications	Phytoestrogenic; aromatase inhibition; cardiovascular; anti-inflammatory; anticancer research
Claim strength	Moderate
Typical form	Red Clover Extract Powder (biochanin A co-delivered with formononetin, daidzein, genistein); Red Clover Liquid Extract
Buy from Herbuno	Trifolium Pratense (Red Clover) Extract Powder → Red Clover Flower Liquid Extract (Water Soluble) - Trifolium pratense →

Name origin: Biochanin A was first isolated from red clover (Trifolium subterraneum initially, then T. pratense) in 1957 by Bickoff et al. The name "biochanin" is derived from "bio" (biological) and "chanin" — a reference to the biochemical isolation context. Structurally, biochanin A is genistein's 4′-methyl ether — the para-hydroxyl of genistein's B-ring is methylated, reducing direct ER binding affinity but creating a depot precursor that is O-demethylated in vivo to release genistein. Traditional use: Red clover (Trifolium pratense) has been used in European folk medicine for menopausal symptoms, cough, skin conditions, and respiratory ailments. Its estrogenic activity was first observed in sheep grazing on subterranean clover in Australia in the 1940s — "clover disease" causing reproductive failure in ewes led directly to isoflavone discovery and isolation. Traditional Australian and European herbal preparations used red clover for menopausal hot flush support before the isoflavone mechanism was understood. Research trajectory: Biochanin A acts as a prodrug for genistein — the 4′-methoxy group is removed by intestinal and hepatic O-demethylases to yield genistein, extending the duration of phytoestrogenic exposure. It also has independent biological activity as an aromatase (CYP19A1) inhibitor and anti-inflammatory agent. Commercial source: Biochanin A is available from Herbuno via Trifolium Pratense Red Clover Extract Powder and Red Clover Flower Liquid Extract, which deliver biochanin A alongside formononetin, daidzein, and genistein as the characteristic red clover isoflavone quartet.

---

Evidence for Biochanin A Applications

Phytoestrogenic activity (via genistein conversion): Biochanin A is O-demethylated to genistein in vivo by intestinal microbiota and hepatic CYP enzymes, with conversion efficiency of 40–70%. In this capacity, red clover preparations delivering biochanin A contribute sustained genistein exposure beyond direct dietary genistein. RCTs with standardised red clover isoflavone preparations (providing 40–160 mg/day total isoflavones including biochanin A) demonstrate significant reduction in menopausal hot flush frequency. Claim strength: Moderate.

Aromatase inhibition (CYP19A1): Biochanin A directly inhibits aromatase with IC₅₀ values of 5–15 μM in cell-free assays — comparable to or exceeding genistein's aromatase inhibition. The 4′-methoxy group alters the spatial fit in the aromatase active site, giving biochanin A distinct selectivity versus genistein. In breast cancer cell models, biochanin A at 10–50 μM reduces oestradiol production and proliferation of ER-positive cells. Claim strength: Moderate (preclinical).

Anti-inflammatory: Biochanin A inhibits NF-κB, COX-2, and 5-LOX at micromolar concentrations. NLRP3 inflammasome suppression and microglial activation inhibition have been characterised in neuroinflammation models — positioning biochanin A as a neuroprotective anti-inflammatory candidate distinct from genistein's primarily peripheral activity profile. Claim strength: Moderate.

Cardiovascular: In the context of red clover isoflavone RCTs, biochanin A contributes to the modest but consistent LDL-lowering and endothelial function improvements observed for the total isoflavone mixture. Platelet aggregation inhibition and nitric oxide upregulation are documented in cell models. Claim strength: Moderate (mixture); Emerging (isolated).

---

Dosage & Formulator Specification

Red clover isoflavone preparations studied in menopausal RCTs deliver 40–160 mg/day total isoflavones — biochanin A typically represents 30–40% of red clover's isoflavone profile. At the standard Promensil® dose of 40 mg/day total isoflavones, biochanin A contributes approximately 12–16 mg. Clinical evidence suggests the whole red clover isoflavone quartet (biochanin A + formononetin + daidzein + genistein) provides synergistic phytoestrogenic activity superior to any single isoflavone in isolation.

For aromatase inhibition applications, biochanin A at concentrations achievable from red clover extract (estimated 1–10 μM plasma after 80 mg/day total isoflavone supplementation) falls below in vitro IC₅₀ values — meaning clinical aromatase inhibition at supplement doses is modest. Higher-standardisation preparations or combination with other aromatase-modulatory compounds (chrysin, resveratrol) are required for meaningful in vivo enzyme modulation.

Red Clover Extract from Herbuno standardised to total isoflavones provides the natural biochanin A:formononetin:daidzein:genistein distribution. For biochanin A-specific standardisation, HPLC quantification is available on request; total isoflavone content ≥8% with isoflavone profiling showing the characteristic red clover ratio is the appropriate quality specification.

Red clover isoflavone preparations carry the same safety considerations as other phytoestrogens: caution in ER-positive hormone-sensitive conditions; thyroid peroxidase inhibition at very high doses; avoid in pregnancy. Red clover additionally contains coumestans — including trace coumestrol — which are more potent phytoestrogens than isoflavones; this should be noted in products targeting oestrogen-sensitive conditions.

---

Frequently Asked Questions — Biochanin A

What is the difference between biochanin A and genistein?
Biochanin A is genistein's 4′-methyl ether — the para-hydroxyl of genistein's B-ring is methylated. In vivo, intestinal and hepatic O-demethylases convert biochanin A to genistein, making biochanin A a dietary prodrug for genistein. Biochanin A's independent activities (aromatase inhibition, anti-neuroinflammatory) differ subtly from genistein's, reflecting the distinct spatial fit of the 4′-methoxy group in enzyme active sites.

Why does red clover contain four isoflavones rather than just genistein?
Red clover biosynthesises a characteristic quartet: biochanin A (genistein 4′-methyl ether), formononetin (daidzein 4′-methyl ether), daidzein, and genistein — reflecting sequential methylation steps in the isoflavone pathway. The methylated forms (biochanin A, formononetin) may represent storage or transport forms in the plant, with demethylation occurring during digestion to release the active aglycones (genistein, daidzein) for biological activity.

Is red clover safer than soy isoflavones for long-term use?
Both have similar safety profiles at equivalent isoflavone doses. Red clover's profile differs from soy in: (1) higher biochanin A and formononetin content (requiring in vivo demethylation to active forms — potentially slower onset); (2) presence of coumestrol (trace amounts — more potent phytoestrogen than isoflavones); (3) distinct glycoside profile affecting absorption kinetics. Multiple long-term RCTs (1–3 years) with Promensil® red clover extract have demonstrated an acceptable safety profile in peri-menopausal women.

Which Herbuno products provide biochanin A?
Trifolium Pratense Red Clover Extract Powder and Red Clover Flower Liquid Extract both deliver biochanin A as part of the characteristic red clover isoflavone quartet. Berseem Clover Extract (Trifolium alexandrinum) is a related species and secondary source. For precise biochanin A quantification, HPLC isoflavone profiling of the specific lot is required; contact Herbuno for analytical documentation.

Related compounds: Formononetin, Genistein, Daidzein, Coumestrol

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery